Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HQI
|
|||
| Former ID |
DCL001200
|
|||
| Drug Name |
ISIS-EIF4E
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Prostate cancer [ICD-11: 2C82.0] | Phase 2 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2] | ||
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) | Target Info | . | [2] |
| KEGG Pathway | RNA transport | |||
| WikiPathways | Translation Factors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.